Category: Recombination
South Africa: BA.4 and BA.5 increasing as a proportion of sequenced cases *1 UPDATE*
An increasing share of South Africa’s Covid-19 cases are the BA.4 and BA.5 sub-lineages of the Omicron variant, suggesting those might have a growth advantage over others, Prof Helen Rees said on Thursday. More...
Japan: New BA.1/BA.2 recombinant discovered
Japanese researchers have detected a new type of the Omicron variant which is a recombination of the BA.1 and more contagious BA.2 strains of the Omicron. More...
France: XD recombinant lacks a competitive advantage over BA.2
France has just published a new risk analysis for SARS-CoV-2 variants circulating in the country. More...
Italy: Omicron recombinants XJ and XL at 32% of sequences in Sardinia
Recent Italian SARS-CoV-2 genome sequencing information has shown that the Omicron BA1/BA2 recombinants XJ and XL are making strong headway on the island of Sardinia. More...
South Korea: XE and XM recombinants may be ‘domestic occurrence’
South Korea’s health authority has detected the XE and XM SARS_CoV-2 recombinant mutations for the first time.
China: 50 SARS-CoV-2 sequences uploaded to Gisaid
Gisaid have published a report recently on fifty SARS-CoV-2 genome sequences uploaded by China which seems to have gone largely unnoticed by the mainstream media. More...
Australia: 12 Deltacron cases in Queensland, 1 in New South Wales
12 cases of the new Deltacron Covid strain have been detected in Queensland just hours after first appearing Australia. More...
Italy: Two cases of XJ recombinant confirmed in Reggio Calabria
“A new variant of Omicron, called XJ was isolated for the first time in Italy from a laboratory in Reggio Calabria. More...
India: XE and XM recombinants reported in Gujurat
India has confirmed its first cases in the XE and XM recombinant variants in Gujurat. More...
France: XD Deltacron recombinant update
France has issued its latest epidemiological update which gives more details on the growth and characteristics of the XD Deltacron recombinant. More...